|
Volumn 127, Issue 17, 2016, Pages 2122-2130
|
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
a a a a a a a a a a a a a a a a a a a a more.. |
Author keywords
[No Author keywords available]
|
Indexed keywords
ATM PROTEIN;
ATM PROTEIN, HUMAN;
BIRC3 PROTEIN, HUMAN;
INHIBITOR OF APOPTOSIS PROTEIN;
NOTCH1 PROTEIN, HUMAN;
NOTCH1 RECEPTOR;
PHOSPHOPROTEIN;
PROTEIN P53;
RNA SPLICING FACTOR;
SF3B1 PROTEIN, HUMAN;
TP53 PROTEIN, HUMAN;
TUMOR PROTEIN;
UBIQUITIN PROTEIN LIGASE;
ADULT;
AGED;
CANCER STEM CELL;
CELL CLONE;
DISEASE COURSE;
DNA MUTATIONAL ANALYSIS;
FEMALE;
GENETICS;
HUMAN;
KAPLAN MEIER METHOD;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
MALE;
MIDDLE AGED;
MOLECULAR EVOLUTION;
MUTATION;
PHYSIOLOGY;
PROGNOSIS;
TIME TO TREATMENT;
TREATMENT OUTCOME;
TUMOR SUPPRESSOR GENE;
VERY ELDERLY;
YOUNG ADULT;
ADULT;
AGED;
AGED, 80 AND OVER;
ATAXIA TELANGIECTASIA MUTATED PROTEINS;
CLONE CELLS;
DISEASE PROGRESSION;
DNA MUTATIONAL ANALYSIS;
EVOLUTION, MOLECULAR;
FEMALE;
GENES, P53;
HUMANS;
INHIBITOR OF APOPTOSIS PROTEINS;
KAPLAN-MEIER ESTIMATE;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
MALE;
MIDDLE AGED;
MUTATION;
NEOPLASM PROTEINS;
NEOPLASTIC STEM CELLS;
PHOSPHOPROTEINS;
PROGNOSIS;
RECEPTOR, NOTCH1;
RNA SPLICING FACTORS;
TIME-TO-TREATMENT;
TREATMENT OUTCOME;
TUMOR SUPPRESSOR PROTEIN P53;
UBIQUITIN-PROTEIN LIGASES;
YOUNG ADULT;
|
EID: 85011375984
PISSN: None
EISSN: 15280020
Source Type: Journal
DOI: 10.1182/blood-2015-07-659144 Document Type: Article |
Times cited : (275)
|
References (0)
|